Philip James PetersJanet M. McNichollBoonyos RaengsakulrachPunneeporn WasinrapeeFamui MueanpaiWinai RatanasuwanPoj IntalapapornJan DrobeniucSumathi RamachandranHong ThaiGuo Liang XiaSaleem KamiliYury KhudyakovPaul J. WeidleChong Gee TeoMichelle S. McConnellCenters for Disease Control and PreventionThailand Ministry of Public HealthMahidol UniversityRajavithi Hospital2018-10-192018-10-192013-09-01Journal of the International Association of Providers of AIDS Care. Vol.12, No.5 (2013), 349-35323259582232595742-s2.0-84884699180https://repository.li.mahidol.ac.th/handle/20.500.14594/31879Coinfection with HIV and hepatitis B virus (HBV) is common in resource-limited settings but is frequently not diagnosed. The authors retrospectively tested specimens for HBV in HIV-infected Thai women who had participated in an antiretroviral therapy (ART) clinical study. A substantial proportion (27 of 211; 13%) of HIV-infected women were HBV coinfected. Among HIV/HBV-coinfected women, the authors observed similar rates of antiretroviral-associated liver toxicity (despite nevirapine [NVP] use) and CD4 count reconstitution as observed in HIV-monoinfected women. Hepatitis B surface antigen (HBsAg) screening detected the majority (81%) of HBV coinfections, including all 5 HBV-coinfected women who did not suppress HBV despite 48 weeks of lamivudine (3TC)-containing ART and could be used to tailor ART for patients diagnosed with HBV coinfection in accordance with World Health Organization guidelines. Although HBsAg screening did not diagnose 5 occult HBV coinfections, these women achieved HBV suppression on 3TC-containing ART, suggesting that not detecting occult HBV coinfection would have limited clinical impact. © The Author(s) 2013.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS10.1177/2325957413488201